Cboe BZX · EDGEHealthcarePharmaceuticals

MRBL Enhanced Equity ETF news

$51.97−0.54%

Close Sep 28, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About MRBL Enhanced Equity ETF

No recent articles focused on MRBL Enhanced Equity ETF.

Also mentions EDGE

Articles that tag EDGE but are mainly about other companies.

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire Inc.Jul 21, 1:00 PM ET▲ Positive

Developing Versamune HPV, a therapeutic cancer vaccine with notable clinical potential and considered among the most promising investigational therapies for HPV-positive HNSCC.

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire Inc.Jul 13, 1:00 PM ET▲ Positive

Developing Versamune HPV and PDS0101, therapeutic cancer vaccines with demonstrated clinical potential in HNSCC. The company is well-positioned in the growing therapeutic vaccine segment.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology